Tango Therapeutics, Inc. (TNGX)Healthcare | Biotechnology | Boston, United States | NasdaqGM
22.19 USD
-0.03
(-0.135%) ⇩
(Oct. 14, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 6:45 a.m. EDT
Tango Therapeutics presents a classic biotech dilemma: massive analyst optimism versus deteriorating operational reality. The fundamental picture is stark; the company is burning cash with negative gross and operating margins, and despite a recent price recovery, the five-year trajectory remains down nearly 30%. The market has priced in a 'value trap' scenario where the low share price reflects the risk of running out of cash before a blockbuster drug hits. While analysts see massive upside based on potential clinical success, the lack of revenue and negative free cash flow make this a high-risk speculative play rather than a solid investment. The options market confirms this anxiety, with traders buying protection at levels far below the current price, anticipating a crash if the next trial results disappoint. Until the company demonstrates a clear path to profitability or a confirmed milestone that changes the revenue equation, the risk-reward profile remains skewed against the buyer. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.085575 |
| AutoETS | 0.090863 |
| MSTL | 0.091033 |
| AutoTheta | 0.176024 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 6.74 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.498 |
| Excess Kurtosis | -0.59 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.123 |
| Revenue per Share | 0.398 |
| Market Cap | 3,741,464,064 |
| Forward P/E | -13.17 |
| Beta | 1.17 |
| Profit Margins | -229.92% |
| Website | https://www.tangotx.com |
As of Oct. 10, 2026, 6:45 a.m. EDT: Speculators are positioning defensively with heavy put volume and open interest concentrated at strikes significantly below the current price (e.g., $10, $12, $18), suggesting a fear of a significant downside gap. While there is some call activity near the money, the overwhelming open interest in deep out-of-the-money puts indicates a market expectation of volatility driven by bad news or a failure to meet high analyst expectations, rather than a bullish breakout.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.4198472 |
| Address1 | 201 Brookline Avenue |
| Address2 | Suite 901 |
| All Time High | 34.39 |
| All Time Low | 1.03 |
| Ask | 36.82 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 4,195,070 |
| Average Daily Volume3 Month | 2,789,954 |
| Average Volume | 2,789,954 |
| Average Volume10Days | 4,195,070 |
| Beta | 1.17 |
| Bid | 21.55 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 6.085 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 22.19 |
| Current Ratio | 50.824 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 23.02 |
| Day Low | 21.52 |
| Debt To Equity | 3.123 |
| Display Name | Tango Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,786,451,400 |
| Earnings Timestamp End | 1,793,795,400 |
| Earnings Timestamp Start | 1,793,795,400 |
| Ebitda | -134,424,992 |
| Ebitda Margins | -2.4981 |
| Enterprise To Ebitda | -20.528 |
| Enterprise To Revenue | 51.281 |
| Enterprise Value | 2,759,465,984 |
| Eps Current Year | -1.39615 |
| Eps Forward | -1.68524 |
| Eps Trailing Twelve Months | -0.85 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 24.2208 |
| Fifty Day Average Change | -2.0307999 |
| Fifty Day Average Change Percent | -0.08384528 |
| Fifty Two Week Change Percent | 141.98473 |
| Fifty Two Week High | 34.39 |
| Fifty Two Week High Change | -12.199999 |
| Fifty Two Week High Change Percent | -0.35475427 |
| Fifty Two Week Low | 6.69 |
| Fifty Two Week Low Change | 15.5 |
| Fifty Two Week Low Change Percent | 2.316891 |
| Fifty Two Week Range | 6.69 - 34.39 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,599,139,800,000 |
| Float Shares | 120,671,067 |
| Forward Eps | -1.68524 |
| Forward P E | -13.167264 |
| Free Cashflow | -71,874,872 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 137 |
| Fullday Change | -0.19000053 |
| Fullday Change Percent | -0.8562439 |
| Fullday Price | 22.0 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | -1.48369 |
| Gross Profits | -79,839,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01191 |
| Held Percent Institutions | 1.28536 |
| Implied Shares Outstanding | 168,610,367 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts. |
| Long Name | Tango Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 3,741,464,064 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_424111353 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -123,721,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,125,895,680 |
| Number Of Analyst Opinions | 11 |
| Open | 21.98 |
| Operating Cashflow | -143,896,000 |
| Operating Margins | -2.53381 |
| Overall Risk | 8 |
| Phone | 857 320 4900 |
| Pre Market Change | -0.19000053 |
| Pre Market Change Percent | -0.8562439 |
| Pre Market Price | 22.0 |
| Pre Market Time | 1,792,065,641 |
| Previous Close | 22.22 |
| Price Eps Current Year | -15.893708 |
| Price Hint | 2 |
| Price To Book | 3.6466722 |
| Price To Sales Trailing12 Months | 69.529724 |
| Profit Margins | -2.29918 |
| Quick Ratio | 49.953 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | -0.02999878 |
| Regular Market Change Percent | -0.135008 |
| Regular Market Day High | 23.02 |
| Regular Market Day Low | 21.52 |
| Regular Market Day Range | 21.52 - 23.02 |
| Regular Market Open | 21.98 |
| Regular Market Previous Close | 22.22 |
| Regular Market Price | 22.19 |
| Regular Market Time | 1,792,008,001 |
| Regular Market Volume | 3,438,781 |
| Return On Assets | -0.12993 |
| Return On Equity | -0.21340999 |
| Revenue Per Share | 0.398 |
| Sand P52 Week Change | 0.16440773 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 168,610,367 |
| Shares Percent Shares Out | 0.26389998 |
| Shares Short | 44,500,110 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 42,627,550 |
| Short Name | Tango Therapeutics, Inc. |
| Short Percent Of Float | 0.2669 |
| Short Ratio | 15.15 |
| Source Interval | 15 |
| State | MA |
| Symbol | TNGX |
| Target High Price | 69.0 |
| Target Low Price | 24.0 |
| Target Mean Price | 45.18182 |
| Target Median Price | 40.0 |
| Total Cash | 1,013,990,016 |
| Total Cash Per Share | 6.014 |
| Total Debt | 31,992,000 |
| Total Revenue | 53,811,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.85 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 21.516476 |
| Two Hundred Day Average Change | 0.67352486 |
| Two Hundred Day Average Change Percent | 0.03130275 |
| Type Disp | Equity |
| Volume | 3,438,781 |
| Website | https://www.tangotx.com |
| Zip | 2,215 |